Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

DOI: 10.1073/pnas.0409336102
Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2273-6.

#	Paper	IF	Citations
741	Nanomedicine: a new paradigm in diagnosis and therapy. **2005**,		1
740	Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. **2005**, 1, 101-9		248
739	Imaging amyloid beta peptide oligomeric particles in solution. **2005**, 13, 5213-7		14
738	Nanostructures in biodiagnostics. **2005**, 105, 1547-62		4122
737	Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. **2005**, 95, 834-47		467
736	Research Highlights. **2005**, 23, 311-311		1
735	Genetically engineered livestock: closer than we think?. **2005**, 23, 533-5		14
734	En route to early diagnosis of Alzheimer's disease--are we there yet?. **2005**, 23, 531-3		20
733	DNA-Based Assembly of Metal Nanoparticles. **2005**, 2005, 3641-3655		107
732	Nanomaterial-based amplified transduction of biomolecular interactions. **2005**, 1, 1036-43		370
731	Optically and Chemically Encoded Nanoparticle Materials for DNA and Protein Detection. **2005**, 30, 376-380		43
730	Nanoscience enables ultrasensitive detection of Alzheimer's biomarker. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 2263-4	11.5	49
729	Epithelial lining fluid solute concentrations in chronic obstructive lung disease patients and normal subjects. **2005**, 99, 1286-92		68
728	The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. **2005**, 115, 1121-9		178
727	A bio-bar-code assay based upon dithiothreitol-induced oligonucleotide release. **2005**, 77, 8174-8		161
726	CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. **2005**, 5, 661-72		99
725	Key roles for chain flexibility in block copolymer membranes that contain pores or make tubes. **2005**, 5, 2343-9		71

724	Colorimetric bio-barcode amplification assay for cytokines. **2005**, 77, 6985-8	114
723	Point-of-care molecular diagnostic systems--past, present and future. **2005**, 8, 504-9	121
722	Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. **2005**, 336, 1268-77	173
721	Nanotechnology in clinical laboratory diagnostics. **2005**, 358, 37-54	318
720	Microarray-based detection of protein binding and functionality by gold nanoparticle probes. **2005**, 77, 5770-4	146
719	The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. **2006**, 6, 1682-6	195
718	Analysis of the inter- and extracellular formation of platinum nanoparticles by Fusarium oxysporum f. sp. lycopersici using response surface methodology. **2006**, 17, 3482-9	200
717	From homoligand- to mixed-ligand- monolayer-protected metal nanoparticles: a scanning tunneling microscopy investigation. **2006**, 128, 11135-49	174
716	Cytotoxic Intermediates in the Fibrillation Pathway: A□Oligomers in Alzheimer□ Disease as a Case Study. **2006**, 60-81	1
715	Multiplexed detection of protein cancer markers with biobarcoded nanoparticle probes. **2006**, 128, 8378-9	385
714	A bio-barcode assay for on-chip attomolar-sensitivity protein detection. **2006**, 6, 1293-9	191
713	Protein detection using biobarcodes. **2006**, 2, 470-6	11
712	Detection of protein analytes via nanoparticle-based bio bar code technology. **2006**, 78, 2055-9	124
711	Maximizing DNA loading on a range of gold nanoparticle sizes. **2006**, 78, 8313-8	887
710	Bimetallic silver□gold nanowires: fabrication and use in surface-enhanced Raman scattering. **2006**, 16, 3929-3935	160
709	Synaptic targeting by A beta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. **2006**, 2, 43-55	86
708	Fluoroimmunoassay for antigen based on fluorescence quenching signal of gold nanoparticles. **2006**, 78, 1104-6	165
707	Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. **2006**, 26, 6011-8	408

706	Nanodiagnostics: a new frontier for clinical laboratory medicine. **2006**, 52, 1238-46	145
705	A selected history and future of immunoassay development and applications in clinical chemistry. **2006**, 369, 119-24	104
704	Gold nanoparticle probes for the detection of nucleic acid targets. **2006**, 363, 120-6	290
703	Multipole plasmon resonances in gold nanorods. **2006**, 110, 2150-4	296
702	Multifunctional Nanoparticles for Cancer Therapy. **2006**, 59-75	
701	BIOSENSORS BASED ON GOLD NANOPARTICLE LABELING. **2006**, 429-466	1
700	Biomarkers for Alzheimer's disease--clinical needs and application. **2005**, 8, 339-46	54
699	Application of Nanoscale Bioassemblies to Clinical Laboratory Diagnostics. **2006**, 41, 23-48	2
698	Toward the emergence of nanoneurosurgery: part II--nanomedicine: diagnostics and imaging at the nanoscale level. **2006**, 58, 805-23; discussion 805-23	84
697	Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. **2006**, 23, 251-60	221
696	Cyclooxygenase-dependent lipid-modification of brain proteins. **2005**, 15, 139-42	26
695	Alzheimer's disease: A needle from the haystack. **2006**, 440, 284-5	18
694	Chemical biology: a pocketful of colour. **2006**, 440, 285	2
693	Designed DNA molecules: principles and applications of molecular nanotechnology. **2006**, 7, 565-75	119
692	High interest in screening and treatment for mild cognitive impairment in older adults: A pilot study. **2006**, 54, 1388-94	21
691	Biotin-avidin interaction-based screening assay for Alzheimer's beta-peptide oligomer inhibitors. **2006**, 356, 265-72	38
690	Toward the detection of single virus particle in serum. **2006**, 356, 161-70	19
689	Nanotechnologies for biomolecular detection and medical diagnostics. **2006**, 10, 11-9	408

688	Nanoparticle-mediated local and remote manipulation of protein aggregation. **2006**, 6, 110-5	256
687	The study of Alzheimer's disease biomarkers. **2006**, 2, 5-16	15
686	Multisegmented one-dimensional nanorods prepared by hard-template synthetic methods. **2006**, 45, 2672-92	447
685	Multiplexed DNA detection with biobarcoded nanoparticle probes. **2006**, 45, 3303-6	231
684	Proteolytic actuation of nanoparticle self-assembly. **2006**, 45, 3161-5	127
683	Reversible binding of fluorescent proteins at DNA-gold nanoparticles. **2006**, 45, 6827-30	38
682	Designed fabrication of multifunctional magnetic gold nanoshells and their application to magnetic resonance imaging and photothermal therapy. **2006**, 45, 7754-8	453
681	Vielsegmentige Nanostäbe: Templatsynthese und Eigenschaften. **2006**, 118, 2738-2759	41
680	Multiplexed DNA Detection with Biobarcoded Nanoparticle Probes. **2006**, 118, 3381-3384	52
679	Proteolytic Actuation of Nanoparticle Self-Assembly. **2006**, 118, 3233-3237	18
678	Reversible Binding of Fluorescent Proteins at DNA□Gold Nanoparticles. **2006**, 118, 6981-6984	7
677	Designed Fabrication of Multifunctional Magnetic Gold Nanoshells and Their Application to Magnetic Resonance Imaging and Photothermal Therapy. **2006**, 118, 7918-7922	142
676	Dendrimer-Scaffold-Based Electron-Beam Patterning of Biomolecules. **2006**, 18, 315-319	30
675	Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there?. **2006**, 6, 1293-306	19
674	Genotoxicity in Alzheimer's disease: role of amyloid. **2006**, 3, 365-75	9
673	Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease. **2006**, 3, 95-108	41
672	Genetic and pharmacological basis for therapeutic inhibition of beta- and gamma-secretases in mouse models of Alzheimer's memory deficits. **2006**, 17, 429-54	25
671	The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. **2006**, 6, 597-608	96

670	ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. **2006**, 281, 20315-25	138
669	Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. **2006**, 20, 2576-8	97
668	Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. **2007**, 27, 796-807	945
667	Emerging technologies for point-of-care genetic testing. **2007**, 7, 359-70	43
666	From molecular diagnostics to personalized testing. **2007**, 8, 85-99	10
665	Advances on the understanding of the origins of synaptic pathology in AD. **2007**, 8, 486-508	28
664	Metal nanoparticle-based detection for DNA analysis. **2007**, 8, 274-85	17
663	High-throughput assembly of nanoelements in nanoporous alumina templates. **2007**, 90, 163119	16
662	Memories: Molecules and Circuits. **2007**,	2
661	Current state and future directions of neurochemical biomarkers for Alzheimer's disease. **2007**, 45, 1421-34	58
660	Beta-amyloid modulation of synaptic transmission and plasticity. **2007**, 27, 11832-7	94
659	Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods. **2007**, 23, 246-50	23
658	Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome. **2007**, 24, 369-74	29
657	Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease. **2007**, 30, 1-32	
656	Biomimetic Nanosensors. **2007**,	
655	Detection of amyloid-beta oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer. **2007**, 11, 117-25	57
654	Nanoparticle-Based biobarcode amplification assay (BCA) for sensitive and early detection of human immunodeficiency type 1 capsid (p24) antigen. **2007**, 46, 231-7	73
653	Introduction to nanotechnology: potential applications in physical medicine and rehabilitation. **2007**, 86, 225-41	13

652	Single particle detection of Abeta aggregates associated with Alzheimer's disease. **2007**, 364, 902-7	41
651	beta-Sheet structured beta-amyloid(1-40) perturbs phosphatidylcholine model membranes. **2007**, 368, 982-97	71
650	Botulism diagnostics: from clinical symptoms to in vitro assays. **2007**, 33, 109-25	94
649	Biomedical nanotechnology for cancer. **2007**, 91, 899-927	19
648	Decorating carbon nanotubes with metal or semiconductor nanoparticles. **2007**, 17, 2679	574
647	Advances and challenges of nanotechnology-based drug delivery systems. **2007**, 4, 621-33	86
646	In vitro cytotoxicitiy of silica nanoparticles at high concentrations strongly depends on the metabolic activity type of the cell line. **2007**, 41, 2064-8	325
645	Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. **2007**, 103, 334-45	122
644	Aspects of beta-amyloid as a biomarker for Alzheimer's disease. **2007**, 1, 59-78	65
643	Cognition Enhancers. **2007**, 241-283	5
642	Molecular Dynamics Simulation Study of Self-Assembled Monolayers of Alkanethiol Surfactants on Spherical Gold Nanoparticles**2007**, 111, 15857-15862	169
641	Biosensors and Bio-Bar Code Assays Based on Biofunctionalized Magnetic Microbeads. **2007**, 7, 589-614	105
640	Biosensing with plasmonic nanoparticles. **2007**, 219-270	3
639	Microarray-based kinase inhibition assay by gold nanoparticle probes. **2007**, 79, 773-7	53
638	Immunomagnetic diffractometry for detection of diagnostic serum markers. **2007**, 129, 15824-9	57
637	Homogeneous detection of nucleic acids based upon the light scattering properties of silver-coated nanoparticle probes. **2007**, 79, 6650-4	94
636	Nanoparticle self-assembly gated by logical proteolytic triggers. **2007**, 129, 6064-5	116
635	Nonenzymatic detection of bacterial genomic DNA using the bio bar code assay. **2007**, 79, 9218-23	112

634	Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. **2007**, 282, 11590-601	654
633	Ultrasensitive electrochemical detection of proteins by amplification of aptamer-nanoparticle bio bar codes. **2007**, 79, 8024-9	120
632	Nanotechnology in the diagnosis and management of heart, lung and blood diseases. **2007**, 7, 149-60	18
631	Nanotechnologies for Diagnosis Present and Future. **2007**,	
630	Ultrasensitive assays for proteins. **2007**, 132, 724-37	118
629	Amyloid-beta aggregation. **2007**, 4, 13-27	244
628	. **2007**,	7
627	Direct detection of nucleic acids by tagging phosphates on their backbones with conductive nanoparticles. **2007**, 46, 2051-4	25
626	Colorimetric detection of mercuric ion (Hg2+) in aqueous media using DNA-functionalized gold nanoparticles. **2007**, 46, 4093-6	1124
625	Direct Detection of Nucleic Acids by Tagging Phosphates on Their Backbones with Conductive Nanoparticles. **2007**, 119, 2097-2100	5
624	Colorimetric Detection of Mercuric Ion (Hg2+) in Aqueous Media using DNA-Functionalized Gold Nanoparticles. **2007**, 119, 4171-4174	246
623	Nanoparticle Self-Assembly Directed by Antagonistic Kinase and Phosphatase Activities. **2007**, 19, 3579-3583	41
622	A perspective on bioconjugated nanoparticles and quantum dots. **2007**, 59, 1-10	71
621	Nanobarcode gene expression monitoring system for potential miniaturized space applications. **2007**, 40, 513-522	
620	Biosensing: Taking charge of biomolecules. **2007**, 2, 596-7	39
619	Detection of proteins using a colorimetric bio-barcode assay. **2007**, 2, 1438-44	103
618	Monoclonal antibodies that target pathological assemblies of Abeta. **2007**, 100, 23-35	271
617	Advancing translational research with the Semantic Web. **2007**, 8 Suppl 3, S2	165

616	Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. **2007**, 59, 332-45		257
615	Large size fibrillar bundles of the Alzheimer amyloid beta-protein. **2007**, 36, 701-9		12
614	Design von bioaktiven und nanostrukturierten Oberfl□hen. **2007**, 13, 917-930		
613	Laboratory biomarkers in Alzheimer's disease. **2007**, 7, 381-7		6
612	Application of Surface-Enhanced Raman Spectroscopy for Detection of Beta Amyloid Using Nanoshells. **2007**, 2, 55-64		60
611	Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). **2008**, 12, 51S-7S		74
610	Gold nanoparticles for the development of clinical diagnosis methods. *Analytical and Bioanalytical Chemistry*, **2008**, 391, 943-50	4.4	384
609	Quantum-dot-based electrochemical immunoassay for high-throughput screening of the prostate-specific antigen. **2008**, 4, 82-6		111
608	Enzyme□emiconductor interactions: Routes from fundamental aspects to photoactive devices. **2008**, 245, 1884-1898		12
607	Mass spectrometry signal amplification method for attomolar detection of antigens using small-molecule-tagged gold microparticles. **2008**, 47, 9518-21		54
606	Enzyme-Based Multi-Component Optical Nanoprobes for Sequence- Specific Detection of DNA Hybridization. **2008**, 20, 497-500		118
605	Mass Spectrometry Signal Amplification Method for Attomolar Detection of Antigens Using Small-Molecule-Tagged Gold Microparticles. **2008**, 120, 9660-9663		7
604	Electrical impedance spectroscopy investigation of surfactant-magnetite-polypyrrole particles. **2008**, 319, 441-9		38
603	A nanoparticle label/immunochromatographic electrochemical biosensor for rapid and sensitive detection of prostate-specific antigen. **2008**, 23, 1659-65		142
602	Efficient screening of high-signal and low-background antibody pairs in the bio-bar code assay using prion protein as the target. **2008**, 382, 60-2		10
601	Multifunctional nanoparticles--properties and prospects for their use in human medicine. **2008**, 26, 425-33		623
600	Ultrasensitive optical biodiagnostic methods using metallic nanoparticles. **2008**, 3, 215-32		51
599	Targeted proteomics in Alzheimer's disease: focus on amyloid-beta. **2008**, 5, 225-37		43

598	Amyloid beta oligomers induce impairment of neuronal insulin receptors. **2008**, 22, 246-60		431
597	Biosensing with plasmonic nanosensors. **2008**, 7, 442-53		5354
596	Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. **2008**, 1219, 169-79		23
595	Nanoparticle-based biosensors and bioassays. **2008**, 441-457		3
594	Microarray methods for protein biomarker detection. **2008**, 133, 975-83		122
593	Electrochemical DNAzyme sensor for lead based on amplification of DNA-Au bio-bar codes. **2008**, 80, 6323-8		246
592	Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. **2008**, 130, 10258-62		169
591	Peptide antisense nanoparticles. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 17222-6	11.5	96
590	Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. **2008**, 384, 917-28		62
589	Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. **2008**, 2, 889-96		1612
588	Gold nanoparticle-based assays for the detection of biologically relevant molecules. **2008**, 3, 543-53		29
587	Structural classification of toxic amyloid oligomers. **2008**, 283, 29639-43		622
586	Nanoparticle assisted magnetic resonance imaging of the early reversible stages of amyloid beta self-assembly. **2008**, 2197-9		39
585	Nanofluidics: Systems and Applications. **2008**, 8, 441-450		78
584	Fluorescence recovery assay for the detection of protein-DNA binding. **2008**, 80, 5616-21		48
583	Superparamagnetic nanoparticle-polystyrene bead conjugates as pathogen capture mimics: a parametric study of factors affecting capture efficiency and specificity. **2008**, 24, 3493-502		21
582	In situ amplified electrochemical immunoassay for carcinoembryonic antigen using horseradish peroxidase-encapsulated nanogold hollow microspheres as labels. **2008**, 80, 8064-70		189
581	Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 14052-7	11.5	193

580	Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides. **2008**, 5, 268-76		27
579	Amplified transduction of biomolecular interactions based on the use of nanomaterials. **2008**, 109, 239-54		1
578	Chip-based molecular diagnostics using metal nanoparticles. **2008**, 2, 813-28		7
577	Pluronic/chitosan shell cross-linked nanocapsules encapsulating magnetic nanoparticles. **2008**, 19, 1571-83		22
576	Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. **2008**, 5, 233-43		81
575	Role of metal ions in the abeta oligomerization in Alzheimer's disease and in other neurological disorders. **2008**, 5, 500-7		89
574	Stepwise silver-staining-based immunosorbent assay for amyloid-beta autoantibody detection. **2008**, 3, 485-93		4
573	Nanotechnology solutions for Alzheimer's disease: advances in research tools, diagnostic methods and therapeutic agents. **2008**, 13, 199-223		79
572	A method for the detection of amyloid-beta1-40, amyloid-beta1-42 and amyloid-beta oligomers in blood using magnetic beads in combination with Flow cytometry and its application in the diagnostics of Alzheimer's disease. **2008**, 14, 127-31		16
571	Biofunctionalized Magnetic Micro/Nanoparticles for Biosensing Technologies. 169-197		2
570	Drosophila models of Alzheimer's amyloidosis: the challenge of dissecting the complex mechanisms of toxicity of amyloid-beta 42. **2008**, 15, 523-40		48
569	What correlates with the intention to be tested for mild cognitive impairment (MCI) in healthy older adults?. **2008**, 22, 144-52		10
568	. **2008**,		15
567	Nanotechnology in Clinical and Translational Research. **2009**, 123-135		
566	Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 1971-6	11.5	508
565	Electrophilic affibodies forming covalent bonds to protein targets. **2009**, 284, 32906-13		25
564	Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease. **2009**, 284, 4755-9		153
563	Biosensing with plasmonic nanosensors. **2009**, 308-319		79

562	Creutzfeldt-jakob, Parkinson, lewy body dementia and Alzheimer diseases: from diagnosis to therapy. **2009**, 9, 2-11		6
561	ARTIFICIALLY DESIGNED DNA NANOSTRUCTURES. **2009**, 04, 119-139		18
560	Detection of Amyloid-beta aggregates in body fluids: a suitable method for early diagnosis of Alzheimer's disease?. **2009**, 6, 285-9		20
559	A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. **2009**, 29, 4004-15		189
558	A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. **2009**, 66, 190-9		161
557	Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. **2009**, 240, 189-97		105
556	Gold nanoparticle enhanced immuno-PCR for ultrasensitive detection of Hantaan virus nucleocapsid protein. **2009**, 346, 64-70		63
555	Monitoring the amyloid beta-peptide in vivo--caveat emptor. **2009**, 14, 241-51		9
554	Constrained Synthesis and Organization of Catalytically Active Metal Nanoparticles by Self-Assembled Protein Templates. **2009**, 21, 3515-3519		55
553	Cognitive-Performance Recovery of Alzheimer's Disease Model Mice by Modulation of Early Soluble Amyloidal Assemblies. **2009**, 121, 2015-2020		15
552	Bioinspired Colorimetric Detection of Calcium(II) Ions in Serum Using Calsequestrin-Functionalized Gold Nanoparticles. **2009**, 121, 4202-4205		18
551	CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity. **2009**, 30, 1418-29		33
550	Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies. **2009**, 48, 1981-6		114
549	Bioinspired colorimetric detection of calcium(II) ions in serum using calsequestrin-functionalized gold nanoparticles. **2009**, 48, 4138-41		94
548	Localized surface plasmon coupled fluorescence fiber-optic biosensor for alpha-fetoprotein detection in human serum. **2009**, 24, 1610-4		58
547	Sensitivity enhancement in DNA hybridization assay using gold nanoparticle-labeled two reporting probes. **2009**, 25, 435-41		7
546	Bio-inspired colorimetric detection of Hg2+ and Pb2+ heavy metal ions using Au nanoparticles. *Analytical and Bioanalytical Chemistry*, **2009**, 394, 33-46	4.4	180
545	Current status of nanotechnology approaches for cardiovascular disease: a personal perspective. **2009**, 1, 149-55		25

544	Colloidal gold and silver triangular nanoprisms. **2009**, 5, 646-64	712
543	Drivers of biodiagnostic development. **2009**, 462, 461-4	614
542	Matrix-insensitive protein assays push the limits of biosensors in medicine. **2009**, 15, 1327-32	315
541	Automated and ultrasensitive detection of methyl-3-quinoxaline-2-carboxylic acid by using gold nanoparticles probes SIA-rt-PCR. **2009**, 24, 2858-63	27
540	Selectively colorimetric detection of cysteine with triangular silver nanoprisms. **2009**, 20, 611-614	32
539	Attomolar protein detection in complex sample matrices with semi-homogeneous fluidic force discrimination assays. **2009**, 24, 1109-15	61
538	A microfluidic detection system based upon a surface immobilized biobarcode assay. **2009**, 24, 2397-403	35
537	Nano-ELISA for highly sensitive protein detection. **2009**, 24, 2836-41	121
536	Construction of DNA sandwich electrochemical biosensor with nanoPbS and nanoAu tags on magnetic microbeads. **2009**, 24, 3223-8	29
535	Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. **2009**, 38, 1759-82	2188
534	An operationally simple colorimetric assay of hyaluronidase activity using cationic gold nanoparticles. **2009**, 134, 1291-3	40
533	Field-effect enzymatic amplifying detector with picomolar detection limit. **2009**, 81, 7123-6	19
532	Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. **2009**, 29, 10961-73	91
531	In vitro diagnostic prospects of nanoparticles. **2009**, 403, 1-8	101
530	Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. **2009**, 1792, 482-96	231
529	Protein aggregation as a paradigm of aging. **2009**, 1790, 980-96	78
528	Oligomeric aggregates of amyloid beta peptide 1-42 activate ERK/MAPK in SH-SY5Y cells via the alpha7 nicotinic receptor. **2009**, 55, 796-801	38
527	Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer assembly. **2009**, 465, 99-103	57

526	The sea urchin embryo: a model to study Alzheimer's beta amyloid induced toxicity. **2009**, 483, 120-6		15
525	Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. **2009**, 96, 4200-11		83
524	Nanoscale labels: nanoparticles and liposomes in the development of high-performance biosensors. **2009**, 4, 447-67		41
523	Recent advances in nanostructured chemosensors and biosensors. **2009**, 134, 1980-90		144
522	Amplified detection of protein cancer biomarkers using DNAzyme functionalized nanoprobes. **2009** , 6845-7		46
521	Biomolecular sensing via coupling DNA-based recognition with gold nanoparticles. **2009**, 42, 203001		39
520	Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle. **2009**, 3, 2834-40		187
519	Functional nanomaterial-based amplified bio-detection strategies. **2009**, 19, 2107		14
518	[Biomarkers for early diagnosis of Alzheimer's disease: current update and future directions]. **2009**, 165, 511-20		6
517	Detection and Identification of Bioanalytes with High Resolution LSPR Spectroscopy and MALDI Mass Spectrometry. **2009**, 113, 5891-5894		41
516	Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 18437-42	11.5	335
515	Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. **2009**, 8, 65-81		24
514	Neurobiology of cognitive disorders. **2009**, 22, 546-51		20
513	DNA-Modified Nanoparticles: Gold and Silver. **2009**, 405-440		
512	Novel Strategies and Tools for Enhanced Sensitivity in Routine Biomolecule Analytics. **2009**, 5, 390-407		7
511	Analytical Tools for Detecting Amyloid Beta Oligomerisation and Assembly. **2009**, 5, 229-245		10
510	Quantitative and mechanistic studies of Abeta immunotherapy. **2009**, 8, 31-49		39
509	Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. **2010**, 20, 637-46		54

508	Spherical and Anisotropic Silver Nanomaterials in Medical Diagnosis. **2010**,		
507	Interference from heterophilic antibodies in amyloid-β oligomer ELISAs. **2010**, 21, 1295-301		46
506	Nanoparticles for detection and diagnosis. **2010**, 62, 316-28		256
505	Emerging nanotechnology-based strategies for the identification of microbial pathogenesis. **2010**, 62, 408-23		229
504	Application of smart nanostructures in medicine. **2010**, 5, 1129-38		21
503	Separation and characterization of aggregated species of amyloid-beta peptides. *Analytical and Bioanalytical Chemistry*, **2010**, 397, 2357-66	4.4	9
502	Inhibition of beta 1-40 amyloid fibrillation with N-acetyl-L-cysteine capped quantum dots. **2010**, 31, 91-8		115
501	Transgenic Drosophila models of Alzheimer's disease and tauopathies. **2010**, 214, 245-62		74
500	Sensitive detection of Aβ protofibrils by proximity ligation--relevance for Alzheimer's disease. **2010**, 11, 124		32
499	Amyloid beta and APP as biomarkers for Alzheimer's disease. **2010**, 45, 23-9		88
498	Role of the SNK-SPAR pathway in the development of Alzheimer's disease. **2010**, 62, 214-21		10
497	An Aptamer Cross-Linked Hydrogel as a Colorimetric Platform for Visual Detection. **2010**, 122, 1070-1074		53
496	Colorimetric Detection of Glucose in Rat Brain Using Gold Nanoparticles. **2010**, 122, 4910-4914		68
495	An aptamer cross-linked hydrogel as a colorimetric platform for visual detection. **2010**, 49, 1052-6		304
494	Colorimetric detection of glucose in rat brain using gold nanoparticles. **2010**, 49, 4800-4		230
493	Molecular biomimetics: GEPI-based biological routes to technology. **2010**, 94, 78-94		81
492	Nanotechnology tools in pharmaceutical R&D. **2010**, 12, 24-30		33
491	An on-nanoparticle rolling-circle amplification platform for ultrasensitive protein detection in biological fluids. **2010**, 6, 2520-5		52

490	Colorimetric Cu(2+) detection using DNA-modified gold-nanoparticle aggregates as probes and click chemistry. **2010**, 6, 623-6	233
489	N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers. **2010**, 115, 1520-9	123
488	Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. **2010**, 9, 560-74	446
487	Nanoscale Techniques for Biomarker Quantification. **2010**, 457-493	
486	Cerebrospinal Fluid from Alzheimer's disease patients promotes amyloid beta-protein oligomerization. **2010**, 21, 81-6	8
485	CSF Biomarkers for Alzheimer's Disease Diagnosis. **2010**, 2010,	61
484	Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease. **2010**, 5, e10153	100
483	Gold Nanoparticle-Based Biodetection for Chip-Based Portable Diagnosis Systems. **2010**, 15, 107-113	4
482	High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. **2010**, 24, 2716-26	196
481	Protein Nano-Fibrilar Structure and Associated Diseases. **2010**, 7, 116-120	8
480	A novel sensitive immunoassay by nucleic acid barcode dot and its application in the detection of prostate-specific antigen. **2010**, 48, 279-83	6
479	Alzheimer's disease and the amyloid-beta peptide. **2010**, 19, 311-23	806
478	The Polyvalent Gold Nanoparticle Conjugate-Materials Synthesis, Biodiagnostics, and Intracellular Gene Regulation. **2010**, 35, 532-539	27
477	Immobilization of biomolecules on the surface of inorganic nanoparticles for biomedical applications. **2010**, 11, 014101	40
476	Clinical Nanomedicine: Nanomedical approaches in Alzheimer□ disease. **2010**, 3,	1
475	Attenuated antiaggregation effects of magnetite nanoparticles in cerebrospinal fluid of people with Alzheimer's disease. **2010**, 6, 2200-5	7
474	"Smart" diblock copolymers as templates for magnetic-core gold-shell nanoparticle synthesis. **2010**, 10, 85-91	61
473	Immunoassays using polypeptide conjugate binders with tuned affinity. **2010**, 10, 863-7	4

472	Conjugation of fluorescent proteins with DNA oligonucleotides. **2010**, 21, 921-7	22
471	Nanomedicine. **2010**, 615-735	1
470	Amyloid-β(1-40) inhibits amyloid-β(1-42) induced activation of cytoplasmic phospholipase A2 and synapse degeneration. **2010**, 21, 985-93	16
469	Screening kinase inhibitors with a microarray-based fluorescent and resonance light scattering assay. **2010**, 82, 3067-72	43
468	Immunoassay on free-standing electrospun membranes. **2010**, 2, 252-8	21
467	Quantum dot capped magnetite nanorings as high performance nanoprobe for multiphoton fluorescence and magnetic resonance imaging. **2010**, 132, 14803-11	121
466	Functional nanoprobes for ultrasensitive detection of biomolecules. **2010**, 39, 4234-43	492
465	Aptamer-based bio-barcode assay for the detection of cytochrome-c released from apoptotic cells. **2010**, 395, 560-4	37
464	Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. **2010**, 6, 131-44	1328
463	Electrochemiluminescence biobarcode method based on cysteamine--gold nanoparticle conjugates. **2010**, 82, 3099-103	91
462	Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. **2010**, 223, 334-46	120
461	Biochemical markers in Alzheimer's disease clinical trials. **2010**, 4, 91-8	12
460	Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. **2010**, 2, 32	12
459	Effect of polar organic vapors on surface potential of Au nanoparticle aggregates probed by surface-enhanced Raman scattering of 2,6-dimethylphenylisocyanide. **2010**, 46, 3753-5	13
458	Highly sensitive protein detection using enzyme-labeled gold nanoparticle probes. **2010**, 135, 327-31	62
457	Resonance light scattering as a powerful tool for sensitive detection of βamyloid peptide by gold nanoparticle probes. **2011**, 47, 9339-41	55
456	Nucleic acid-functionalized nanomaterials for bioimaging applications. **2011**, 21, 16323	40
455	Development of electrochemical based sandwich enzyme linked immunosensor for Cryptosporidium parvum detection in drinking water. **2011**, 13, 2782-7	22

454	Nanogold-based sensing of environmental toxins: excitement and challenges. **2011**, 29, 52-89	23
453	Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future. **2011**, 8, 413-20	35
452	Heavy-chain complementarity-determining regions determine conformation selectivity of anti-a‖ antibodies. **2011**, 8, 117-23	17
451	DNA-Conjugated Nanomaterials for Bioanalysis. **2011**, 105-126	0
450	A kinetic study of the interaction of DNA with gold nanoparticles: mechanistic aspects of the interaction. **2011**, 13, 1479-89	58
449	Denaturation of proteins near polar surfaces. **2011**, 135, 235103	18
448	Quantitative detection of adenosine in urine using silver enhancement of aptamer-gold nanoparticle aggregation and progressive dilution. **2011**, 47, 4956-8	24
447	A universal method for detection of amyloidogenic misfolded proteins. **2011**, 50, 4322-9	32
446	An abiotic fluorescent probe for cardiac troponin I. **2011**, 133, 14972-4	43
445	The future: biomarkers, biosensors, neuroinformatics, and e-neuropsychiatry. **2011**, 101, 375-400	5
444	Metal Nanoparticles in Microbiology. **2011**,	61
443	Nano-enabled biomarker discovery and detection. **2011**, 5, 387-96	14
442	Enzymatic Synthesis of Platinum Nanoparticles: Prokaryote and Eukaryote Systems. **2011**, 103-134	6
441	A‖42) induced MRI changes in aged rabbit brain resembles AD brain. **2011**, 59, 637-42	9
440	Purified high molecular weight synthetic A‖1-42) and biological A‖oligomers are equipotent in rapidly inducing MTT formazan exocytosis. **2011**, 497, 1-5	5
439	Emerging nanoproteomics approaches for disease biomarker detection: a current perspective. **2011**, 74, 2660-81	53
438	The A‖oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. **2011**, 96, 529-43	314
437	Applications: Nanobiosystems, Medicine, and Health. **2011**, 305-374	3

436 The legacy of nanotechnology: revolution and prospects in neurosurgery. **2011**, 9, 608-14 25

435 Biomarkers in Alzheimer's disease drug development. **2011**, 7, e13-44 87

434 . **2011**, 14

433 Structural and Toxic Properties of Protein Aggregates: Towards a Molecular Understanding of Alzheimer's Disease. **2011**,

432 Biosensors for Cancer Biomarkers. **2011**,

431 Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease. **2011**, 2011, 151645 14

430 Binding of the Same Analyte to Different Biosensor Surfaces. **2011**, 129-168

429 Aggregation state and neurotoxic properties of alzheimer β-amyloid peptide. **2011**, 12, 235-57 14

428 Nanotechnology for Alzheimer's disease detection and treatment. **2011**, 1, 169-193 41

427 Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. **2011**, 7, 521-40 199

426 Rapid and sensitive detection of cytokines using functionalized gold nanoparticle-based immuno-PCR, comparison with immuno-PCR and ELISA. **2011**, 371, 38-47 40

425 Nanoparticle-based bio-barcode assay for the detection of bluetongue virus. **2011**, 178, 225-8 21

424 CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. **2011**, 3, 1188-96 59

423 Surface enhanced optical spectroscopies for bioanalysis. **2011**, 136, 3831-53 104

422 Gold nanoparticle-based signal amplification for biosensing. **2011**, 417, 1-16 294

421 Aβ oligomer-induced synapse degeneration in Alzheimer's disease. **2011**, 31, 939-48 123

420 Fish-on-a-chip: a sensitive detection microfluidic system for Alzheimer's disease. **2011**, 18, 33 19

419 Nanodevices in diagnostics. **2011**, 3, 11-32 51

418	Dissociation of β-amyloid from lipoprotein in cerebrospinal fluid from Alzheimer's disease accelerates β-amyloid-42 assembly. **2011**, 89, 815-21	8
417	Current Status and Future Prospects for Nanoparticle-Based Technology in Human Medicine. **2011**, 781-813	1
416	Advanced Nanoparticles in Medical Biosensors. **2011**, 37-55	
415	Electrochemical immunosensor of tumor necrosis factor α based on alkaline phosphatase functionalized nanospheres. **2011**, 26, 1890-4	103
414	Ultrasensitive biosensing on the zepto-molar level. **2011**, 26, 3386-90	4
413	Universal optical assays based on multi-component nanoprobes for genomic deoxyribonucleic acid and proteins. **2011**, 702, 114-9	4
412	Specificity and sensitivity of the Abeta oligomer ELISA. **2011**, 195, 249-54	27
411	Nanotechniques and Proteomics: An Integrated Platform for Diagnostics,Targeted Therapeutics and Personalized Medicine. **2011**, 9, 264-285	1
410	Alzheimer's disease: pathological mechanisms and recent insights. **2011**, 9, 674-84	35
409	Amyloid-β induced synapse damage is mediated via cross-linkage of cellular prion proteins. **2011**, 286, 37955-37963	78
408	Magnetic particles in ultrasensitive biomarker protein measurements for cancer detection and monitoring. **2011**, 5, 381-391	50
407	A window into the heterogeneity of human cerebrospinal fluid Aβ peptides. **2011**, 2011, 697036	12
406	Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. **2012**, 6, 455-76	83
405	The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients. **2012**, 31, 865-78	28
404	Molecular and Translational Vascular Medicine. **2012**,	
403	Theranostic implications of nanotechnology in multiple sclerosis: a future perspective. **2012**, 2012, 160830	21
402	The Role of Insulin and Insulin-Like Growth Factor-1/FoxO-Mediated Transcription for the Pathogenesis of Obesity-Associated Dementia. **2012**, 2012, 384094	14
401	Molecular tilt on monolayer-protected nanoparticles. **2012**, 97, 36005	6

400	Biomarker Detections Using Functional Noble Metal Nanoparticles. **2012**, 177-205	2
399	Design of β-amyloid aggregation inhibitors from a predicted structural motif. **2012**, 55, 3002-10	42
398	Plasmonic Nanosensors: Review and Prospect. **2012**, 18, 1110-1121	73
397	Quantum dots induce charge-specific amyloid-like fibrillation of insulin at physiological conditions. **2012**,	4
396	A portrait of nanomedicine and its bioethical implications. **2012**, 40, 763-79	13
395	Translational actomyosin research: fundamental insights and applications hand in hand. **2012**, 33, 219-33	34
394	Fluid biomarkers in Alzheimer disease. **2012**, 2, a006221	120
393	Detection of hepatitis B surface antigen by target-induced aggregation monitored by dynamic light scattering. **2012**, 428, 119-25	30
392	Utilization of a multiple antigenic peptide as a calibration standard in the BAN50 single antibody sandwich ELISA for Aβ oligomers. **2012**, 422, 375-80	9
391	Metal compounds as inhibitors of β-amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer's disease. **2012**, 256, 2357-2366	54
390	Neuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain. **2012**, 14, e2	40
389	Biosensors Based on Nanoparticles and Electrochemical Detection. **2012**, 247-267	3
388	Two types of nanoparticle-based bio-barcode amplification assays to detect HIV-1 p24 antigen. **2012**, 9, 180	23
387	Gold nanoparticles in image-guided cancer therapy. **2012**, 393, 154-164	50
386	Metal Nanoparticles in Biomedical Applications. **2012**, 477-519	3
385	Nanotechnology for neurodegenerative disorders. **2012**, 8 Suppl 1, S51-8	60
384	Biochemistry and Biomedical Applications of Spherical Nucleic Acids (SNAs). **2012**, 1-20	6
383	Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. **2012**, 7, e32014	59

382	High-sensitivity nanosensors for biomarker detection. **2012**, 41, 2641-55	232
381	Nanostructured optical microchips for cancer biomarker detection. **2012**, 38, 382-8	36
380	Nanotechnology for neurodegenerative disorders. **2012**, 73, 45-51	67
379	Gold nanoparticles in the clinical laboratory: principles of preparation and applications. **2011**, 50, 193-209	52
378	Interrelations between CSF soluble A‖PP‖amyloid-‖1-42, SORL1, and tau levels in Alzheimer's disease. **2012**, 28, 543-52	21
377	The Handbook of Nanomedicine. **2012**,	27
376	Methods for analysis of amyloid-‖aggregates. **2012**, 28, 735-58	47
375	Synaptotoxic amyloid-‖oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease?. **2013**, 33 Suppl 1, S49-65	96
374	Gold nanoparticle based dot-blot immunoassay for sensitively detecting Alzheimer's disease related ‖amyloid peptide. **2012**, 48, 8392-4	55
373	Amyloid-‖oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. **2012**, 29, 171-6	78
372	Antibodies covalently immobilized on actin filaments for fast myosin driven analyte transport. **2012** , 7, e46298	19
371	Progress on RNAi-based molecular medicines. **2012**, 7, 3971-80	29
370	Gold nanoparticles in biomedical applications: recent advances and perspectives. **2012**, 41, 2256-82	1419
369	Gold nanoparticles in chemical and biological sensing. **2012**, 112, 2739-79	3476
368	Spherical nucleic acids. **2012**, 134, 1376-91	742
367	Gold nanoparticle-enabled biological and chemical detection and analysis. **2012**, 41, 2849-66	557
366	Highly sensitive detection of protein and small molecules based on aptamer-modified electrochemiluminescence nanoprobe. **2012**, 137, 1963-9	19
365	Gold nanoparticles: preparation, properties, and applications in bionanotechnology. **2012**, 4, 1871-80	814

364	Cardiovascular Nanomedicine: Challenges and Opportunities. **2012**, 249-281	2
363	A highly sensitive gold-nanoparticle-based assay for acetylcholinesterase in cerebrospinal fluid of transgenic mice with Alzheimer's disease. **2012**, 1, 90-5	79
362	Surface plasmon polaritons: physics and applications. **2012**, 45, 113001	214
361	Nanomolecular Diagnostics. **2012**, 113-170	1
360	Soluble A□oligomer production and toxicity. **2012**, 120 Suppl 1, 125-139	276
359	Amyloid oligomer detection by immobilized molecular chaperone. **2012**, 61, 28-33	5
358	Peptide-cleaving agents for human islet amyloid polypeptide containing substrate recognition site based on quinoxaline: cleavage efficiency enhanced by lowering substrate concentration. **2012**, 22, 1533-7	15
357	Naphthoquinone-tyrptophan reduces neurotoxic A□56 levels and improves cognition in Alzheimer's disease animal model. **2012**, 46, 663-72	35
356	A nanoparticle-based bio-barcode assay for ultrasensitive detection of ricin toxin. **2012**, 59, 12-6	26
355	Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. **2012**, 134, 8-25	153
354	Fluid biomarkers in Alzheimer's disease - current concepts. **2013**, 8, 20	147
353	A difunctional DNA-AuNP dendrimer coupling DNAzyme with intercalators for femtomolar detection of nucleic acids. **2013**, 49, 7304-6	32
352	Proteins in the electric field near the surface of mica. **2013**, 139, 045102	14
351	Sensitive SNP Detection of KIF6 Gene by Quantum Dot-DNA Conjugate Probe-Based Assay. **2013**, 46, 508-517	3
350	The case for soluble A□oligomers as a drug target in Alzheimer's disease. **2013**, 34, 261-6	93
349	Ultrasensitive microfluidic solid-phase ELISA using an actuatable microwell-patterned PDMS chip. **2013**, 13, 4190-7	64
348	A SERS-based sandwich assay for ultrasensitive and selective detection of Alzheimer's tau protein. **2013**, 14, 3001-9	63
347	Amyloid-□1-42) protofibrils formed in modified artificial cerebrospinal fluid bind and activate microglia. **2013**, 8, 312-22	22

346	Sensitive detection of protein and miRNA cancer biomarkers using silicon-based photonic crystals and a resonance coupling laser scanning platform. **2013**, 13, 4053-64	51
345	Ultrafast molecular motor driven nanoseparation and biosensing. **2013**, 48, 145-52	28
344	An aptamer-based bio-barcode assay with isothermal recombinase polymerase amplification for cytochrome-c detection and anti-cancer drug screening. **2013**, 115, 159-65	49
343	Biomarkers of Neurological Disorders. **2013**, 49-153	
342	A near-infrared, surface-enhanced, fluorophore-linked immunosorbent assay. **2013**, 85, 7102-8	10
341	Brain amyloid-β oligomers in ageing and Alzheimer's disease. **2013**, 136, 1383-98	325
340	Localized surface plasmon resonance: a unique property of plasmonic nanoparticles for nucleic acid detection. **2013**, 5, 12043-71	105
339	Alzheimer's disease biomarkers: correspondence between human studies and animal models. **2013**, 56, 116-30	15
338	Demonstrative experiments about gold nanoparticles and nanofilms: an introduction to nanoscience. **2013**, 46, 319-327	13
337	Gold-nanopatterned single interleukin-6 sandwich immunoassay chips with zeptomolar detection capability based on evanescent field-enhanced fluorescence imaging. **2013**, 138, 3478-82	10
336	Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue. **2013**, 433, 112-20	84
335	Development of Light Waveguide Resonance Light-Scattering Scanner for Microarray Detection. **2013**, 41, 1458-1462	3
334	Protein fibrillation and nanoparticle interactions: opportunities and challenges. **2013**, 5, 2570-88	116
333	Tuning and assembling metal nanostructures with DNA. **2013**, 49, 2597-609	46
332	Glutathione dimerization-based plasmonic nanoswitch for biodetection of reactive oxygen and nitrogen species. **2013**, 7, 2221-30	43
331	The Structure, Energy, Confinement, and Enhancement of Hot Spots between Two Nanoparticles. **2013**, 117, 7744-7750	7
330	New ELISAs with high specificity for soluble oligomers of amyloid β protein detect natural Aβ oligomers in human brain but not CSF. **2013**, 9, 99-112	92
329	Nucleic acid-modified nanostructures as programmable atom equivalents: forging a new "table of elements". **2013**, 52, 5688-98	129

328	Nucleins□remodifizierte Nanostrukturen als programmierbare Atom□quivalente: Entwicklung eines neuen S□stems der Elemente□**2013**, 125, 5798-5809	10
327	Supramolecular self-assemblies as functional nanomaterials. **2013**, 5, 7098-140	519
326	An assessment of the impact of SiO2 nanoparticles of different sizes on the rest/wake behavior and the developmental profile of zebrafish larvae. **2013**, 9, 3161-8	28
325	Ferrite nanoparticles for future heart diagnostics. **2013**, 112, 323-327	11
324	Responsive multidomain free-standing films of gold nanoparticles assembled by DNA-directed layer-by-layer approach. **2013**, 13, 4449-55	46
323	Dimerization of chirally mutated Enkephalin neurotransmitters: implications for peptide and protein aggregation mechanisms. **2013**, 117, 1770-9	8
322	Highly sensitive detection of human IgG using a novel bio-barcode assay combined with DNA chip technology. **2013**, 15, 1	4
321	Integration of biosensors and drug delivery technologies for early detection and chronic management of illness. **2013**, 13, 7680-713	38
320	Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. **2013**, 26, 276-82	19
319	Amyloid-□ligomerization in Alzheimer dementia versus high-pathology controls. **2013**, 73, 104-19	195
318	Quantum dynamical simulations of local field enhancement in metal nanoparticles. **2013**, 25, 125304	18
317	Peptide and Protein-Based Nanoparticles. **2013**, 65-80	
316	The amyloid-□ligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. **2013**, 34, 985-94	54
315	- Chitin Nanofibrils for Biomimetic Products: Nanoparticles and Nanocomposite Chitosan Films in Health Care. **2013**, 704-739	
314	Microfluidics for Neuroscience: Novel Tools and Future Implications. **2013**, 185-211	2
313	TREATMENTS FOR ALZHEIMER□ DISEASE: AN OVERVIEW. **2013**, 4, 12-15	
312	Cellular Internalization of Quantum Dots Mediated by Cell-Penetrating Peptides. **2013**, 1, 151-161	9
311	A Luminex assay detects amyloid □ligomers in Alzheimer's disease cerebrospinal fluid. **2013**, 8, e67898	43

310	Predicting Cognitive Decline in Alzheimer Disease (AD): The Role of Clinical, Cognitive Characteristics and Biomarkers. **2013**,		
309	Biochips as Novel Bioassays. **2013**, 35		1
308	RNA aptamer probes as optical imaging agents for the detection of amyloid plaques. **2014**, 9, e89901		32
307	Immunoprecipitation of amyloid fibrils by the use of an antibody that recognizes a generic epitope common to amyloid fibrils. **2014**, 9, e105433		10
306	Noncovalent interactions of tiopronin-protected gold nanoparticles with DNA: two methods to quantify free energy of binding. **2014**, 2014, 143645		4
305	DNA-based immunoassays for sensitive detection of protein. **2014**, 202, 1248-1256		6
304	Potential applications of magnetic particles to detect and treat Alzheimer's disease. *Nanoscale Research Letters*, **2014**, 9, 538	5	44
303	A promising road with challenges: where are gold nanoparticles in translational research?. **2014**, 9, 2353-70		50
302	Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering. **2014**, 9, 969-80		284
301	Chapter 4:Nanowire Biosensors. **2014**, 167-199		
300	Lab-on-a-Chip and Fluid Manipulation Applications. **2014**, 171-239		1
299	Platelet-activating factor antagonists enhance intracellular degradation of amyloid- 2 in neurons via regulation of cholesterol ester hydrolases. **2014**, 6, 15		9
298	Nanomedicine for Neurological Disorder. **2014**, 109-175		
297	A sensitive a bligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. **2014**, 34, 2884-97		103
296	Detection of misfolded A bligomers for sensitive biochemical diagnosis of Alzheimer's disease. **2014**, 7, 261-8		124
295	Comparison between discrete dipole approximation and other modelling methods for the plasmonic response of gold nanospheres. **2014**, 115, 237-246		21
294	Biomarker modelling of early molecular changes in Alzheimer's disease. **2014**, 18, 213-27		4
293	A sensitive immunosorbent bio-barcode assay based on real-time immuno-PCR for detecting 3,4,3',4'-tetrachlorobiphenyl. *Analytical and Bioanalytical Chemistry*, **2014**, 406, 1693-700	4.4	16

292	Post-genomics nanotechnology is gaining momentum: nanoproteomics and applications in life sciences. **2014**, 18, 111-31	19
291	Use of gold nanoparticles as crosslink agent to form chitosan nanocapsules: study of the direct interaction in aqueous solutions. **2014**, 135, 77-85	19
290	Nanoparticles and their applications in cell and molecular biology. **2014**, 6, 9-26	247
289	Quadratic recycling amplification for label-free and sensitive visual detection of HIV DNA. **2014**, 55, 220-4	43
288	Progress in Designing Artificial Proteases: A New Therapeutic Option for Amyloid Diseases. **2014**, 3, 18-32	11
287	Physicochemical characterization of nanoparticles and their behavior in the biological environment. **2014**, 16, 15053-67	76
286	Folate and biotin based bifunctional quantum dots as fluorescent cell labels. **2014**, 4, 10434	4
285	Physisorption and chemisorption of a self-assembled monolayer by the quartz crystal microbalance. **2014**, 30, 9637-42	5
284	Nanomedicine for Treatment of Cardiovascular Diseases and Stroke. **2014**, 247-298	
283	CSF in Alzheimer's disease. **2014**, 65, 143-72	18
282	Subdiffraction-limited plasmonic imaging with anisotropic metal nanoparticles. **2014**, 86, 2303-7	23
281	Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. **2014**, 6, 42	106
280	Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease. **2014**, 78, 1293-305	32
279	Xanthoceraside rescues learning and memory deficits through attenuating beta-amyloid deposition and tau hyperphosphorylation in APP mice. **2014**, 573, 58-63	36
278	A rapid one-step immunochromatographic test strip for rabies detection using canine serum samples. **2014**, 59, 247-51	5
277	Nanoparticles for Diagnosis and/or Treatment of Alzheimer's Disease. **2014**, 87-179	6
276	Direct Reading of Bona Fide Barcode Assays for Diagnostics with Smartphone Apps. **2015**, 5, 11727	12
275	Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy. **2015**, 46, 817-36	37

274	Super-Resolution Microscopy of Cerebrospinal Fluid Biomarkers as a Tool for Alzheimer's Disease Diagnostics. **2015**, 46, 1007-20		9
273	The elusive nature and diagnostics of misfolded A□oligomers. **2015**, 3, 17		20
272	DNA-Based Nanobiosensors as an Emerging Platform for Detection of Disease. **2015**, 15, 14539-68		74
271	Toward Epileptic Brain Region Detection Based on Magnetic Nanoparticle Patterning. **2015**, 15, 24409-27		10
270	Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. **2015**, 6, 138		38
269	Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. **2015**, 6, 186		19
268	The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. *Frontiers in Neuroscience*, **2015**, 9, 345	5.1	58
267	Cerebrospinal Fluid in Clinical Neurology. **2015**,		13
266	Automatic enumeration of gold nanomaterials at the single-particle level. **2015**, 87, 2576-81		33
265	Real-time monitoring of enzyme-free strand displacement cascades by colorimetric assays. **2015**, 7, 5719-25		23
264	Label-free detection of Alzheimer's disease through the ADP3 peptoid recognizing the serum amyloid-beta42 peptide. **2015**, 51, 718-21		33
263	Amyloid □oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. **2015**, 129, 183-206		359
262	Protein misfolding cyclic amplification (PMCA): Current status and future directions. **2015**, 207, 47-61		28
261	Magnetic resonance beacon to detect intracellular microRNA during neurogenesis. **2015**, 41, 69-78		14
260	Soluble amyloid-□oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. **2015**, 9, 191		205
259	A sensitive quenched electrochemiluminescent DNA sensor based on the catalytic activity of gold nanoparticle functionalized MoS2. **2015**, 39, 8100-8107		28
258	Gold Nanoparticles for In Vitro Diagnostics. **2015**, 115, 10575-636		598
257	A versatile microparticle-based immunoaggregation assay for macromolecular biomarker detection and quantification. **2015**, 10, e0115046		3

256	Application of nanomaterials in the bioanalytical detection of disease-related genes. **2015**, 74, 113-33	61
255	A sensitive colorimetric strategy for monitoring cerebral β-amyloid peptides in AD based on dual-functionalized gold nanoplasmonic particles. **2015**, 51, 8880-3	19
254	Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method. **2015**, 2, 112-23	14
253	Surface layer reflective index changes of Au nanoparticle functionalized porous silicon microcavity for DNA detection. **2015**, 15, 870-876	7
252	Cancer biomarker detection: recent achievements and challenges. **2015**, 44, 2963-97	633
251	A novel ultrasensitive electrochemical DNA sensor based on double tetrahedral nanostructures. **2015**, 71, 434-438	50
250	Nanomaterial-based biosensors using dual transducing elements for solution phase detection. **2015**, 140, 2916-43	27
249	Alzheimer's Disease and Mechanism-Based Attempts to Enhance Cognition. **2015**, 193-231	
248	Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. **2015**, 11, 751-67	79
247	Neuronal stress signaling and eIF2α phosphorylation as molecular links between Alzheimer's disease and diabetes. **2015**, 129, 37-57	46
246	Electrochemical quantification of the Alzheimer's disease amyloid-β(1-40) using amyloid-β fibrillization promoting peptide. **2015**, 6, 7-12	6
245	Horseradish peroxidase and aptamer dual-functionalized nanoprobe for the amplification detection of alpha-methylacyl-CoA racemase. **2015**, 899, 100-5	10
244	A graphene oxide-based fluorescent platform for selective detection of amyloid-β oligomers. **2015**, 7, 8727-8732	22
243	Studying the relationship between cell cycle and Alzheimer's disease by gold nanoparticle probes. **2015**, 489, 32-7	6
242	How many biomarkers to discriminate neurodegenerative dementia?. **2015**, 52, 314-26	14
241	Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence. **2015**, 115, 10530-74	702
240	Self-assembled nanocomposite film with tunable enhanced fluorescence for the detection of DNA. **2015**, 7, 1334-9	14
239	Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. **2015**, 10, 91-8	124

238	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. **2015**, 11, 41-55	116
237	Biosensors for the Determination of Amyloid-Beta Peptides and their Aggregates with Application to Alzheimer's Disease. **2015**, 48, 879-893	8
236	An ultrasensitive electrochemical immunosensor based on the catalytical activity of MoS2-Au composite using Ag nanospheres as labels. **2015**, 206, 30-36	90
235	Methods for the Specific Detection and Quantitation of Amyloid-β Oligomers in Cerebrospinal Fluid. **2016**, 53, 53-67	21
234	A label-free electrochemical immunosensor for beta-amyloid detection. **2016**, 8, 6115-6120	32
233	Citrus bergamia Juice Extract Attenuates β-Amyloid-Induced Pro-Inflammatory Activation of THP-1 Cells Through MAPK and AP-1 Pathways. **2016**, 6, 20809	42
232	Reduction of Blood Amyloid-β Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition. **2016**, 54, 1193-1205	14
231	Synthesis of single-crystalline anisotropic gold nano-crystals via chemical vapor deposition. **2016**, 119, 174301	10
230	A Competitive Bio-Barcode Amplification Immunoassay for Small Molecules Based on Nanoparticles. **2016**, 6, 38114	35
229	Characterization of protein-conjugating kinetics based on localized surface plasmon resonance of the gold nanoparticle. **2016**, 49, 434-443	3
228	Multiparameter Analysis-Based Electrochemiluminescent Assay for Simultaneous Detection of Multiple Biomarker Proteins on a Single Interface. **2016**, 88, 4940-8	30
227	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease. **2016**, 153-179	
226	Bio-inspired nano tools for neuroscience. **2016**, 142, 1-22	35
225	Visual Biopsy by Hydrogen Peroxide-Induced Signal Amplification. **2016**, 88, 10728-10735	13
224	Graphene: Nonreciprocity in Magnetically Biased Graphene at Microwave and Terahertz Frequencies. **2016**, 268-284	
223	Detecting Alzheimer's disease biomarkers: From antibodies to new bio-mimetic receptors and their application to established and emerging bioanalytical platforms - A critical review. **2016**, 940, 21-37	36
222	Alzheimer's Disease Cerebrospinal Fluid (CSF) Biomarkers. **2016**, 139-180	3
221	Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. **2016**, 3, 98-102	47

220	Facile and sensitive detection of influenza viruses using SERS antibody probes. **2016**, 6, 84415-84419		18
219	Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis. **2016**, 13, 603-19		27
218	One-pot green synthesis of anisotropic silver nanoparticles. **2016**, 3, 1259-1264		16
217	Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice. **2016**, 31, 836-47		38
216	Anti-Amyloid-β Immunotherapy for Alzheimer's Disease. **2016**, 193-226		6
215	Fluid Biomarkers and Diagnostics. **2016**, 565-587		
214	Oligonucleotide-based biosensors for in vitro diagnostics and environmental hazard detection. *Analytical and Bioanalytical Chemistry*, **2016**, 408, 2383-406	4.4	13
213	Quantitative nanoimmunosensor based on dark-field illumination with enhanced sensitivity and on-off switching using scattering signals. **2016**, 79, 709-14		5
212	CSF biomarkers in neurodegenerative and vascular dementias. **2016**, 138-140, 36-53		27
211	Nano-biosensors to detect beta-amyloid for Alzheimer's disease management. **2016**, 80, 273-287		112
210	Improving drug delivery technology for treating neurodegenerative diseases. **2016**, 13, 1029-43		22
209	Highly sensitive gold nanoparticles-based optical sensing of DNA hybridization using bis(8-hydroxyquinoline-5-solphonate)cerium(III) chloride as a novel fluorescence probe. **2016**, 118, 356-362		16
208	Green technology for durable finishing of viscose fibers via self-formation of AuNPs. **2017**, 96, 697-705		52
207	Multivalent foldamer-based affinity assay for selective recognition of Aβ oligomers. **2017**, 960, 131-137		5
206	Detection of Aβ oligomers based on magnetic-field-assisted separation of aptamer-functionalized FeO magnetic nanoparticles and BaYF:Yb,Er nanoparticles as upconversion fluorescence labels. **2017**, 170, 350-357		30
205	Graphitic nanocapsules: design, synthesis and bioanalytical applications. **2017**, 9, 10529-10543		8
204	Nucleic acid based polymer and nanoparticle conjugates: Synthesis, properties and applications. **2017**, 88, 136-185		22
203	A Two-Stage Dissociation System for Multilayer Imaging of Cancer Biomarker-Synergic Networks in Single Cells. **2017**, 56, 4802-4805		37

202	A Two-Stage Dissociation System for Multilayer Imaging of Cancer Biomarker-Synergic Networks in Single Cells. **2017**, 129, 4880-4883		7
201	Bioconjugated Nanoparticles for Biosensing, in Vivo Imaging, and Medical Diagnostics. **2017**, 89, 1015-1031		102
200	Single-Molecule Fluorescence Resonance Energy Transfer Studies of Amyloid Clusters in Physiological Solutions. **2017**, 297-311		
199	Drug Delivery to the Brain across the Blood-Brain Barrier Using Nanomaterials. **2017**, 13, 1701921		97
198	Role of membrane GM1 on early neuronal membrane actions of A during onset of Alzheimer's disease. **2017**, 1863, 3105-3116		16
197	The conformational epitope for a new A2 protofibril-selective antibody partially overlaps with the peptide N-terminal region. **2017**, 143, 736-749		13
196	Universal Ratiometric Photoelectrochemical Bioassay with Target-Nucleotide Transduction-Amplification and Electron-Transfer Tunneling Distance Regulation Strategies for Ultrasensitive Determination of microRNA in Cells. **2017**, 89, 9445-9451		60
195	An ultrasensitive enzyme-free electrochemical immunosensor based on redox cycling amplification using methylene blue. **2017**, 142, 3492-3499		29
194	Plasmonic Vertically Coupled Complementary Antennas for Dual-Mode Infrared Molecule Sensing. **2017**, 11, 8034-8046		30
193	Emerging nanotechnology based strategies for diagnosis and therapeutics of urinary tract infections: A review. **2017**, 249, 53-65		31
192	Advances in Alzheimer's Diagnosis and Therapy: The Implications of Nanotechnology. **2017**, 35, 937-953		87
191	Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine. **2017**, 124, 57-78		8
190	Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. **2017**, 1863, 1078-1089		257
189	Metal Nanoparticles in Nanomedicine: Advantages and Scope. **2017**, 121-168		3
188	Applications of Metal Nanoparticles in Medicine/Metal Nanoparticles as Anticancer Agents. **2017**, 169-190		4
187	The Role of Reactive Oxygen Species (ROS) in the Biological Activities of Metallic Nanoparticles. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	417
186	Effects of Acute Toluene Toxicity on Different Regions of Rabbit Brain. **2017**, 2017, 2805370		10
185	Nanotechnology in Clinical and Translational Research. **2017**, 191-205		

184	DNA metallization: principles, methods, structures, and applications. **2018**, 47, 4017-4072		108
183	Gold Nanoparticles Stabilized by Single Tripodal Ligands. **2018**, 35, 1800015		6
182	Signal Amplified Gold Nanoparticles for Cancer Diagnosis on Paper-Based Analytical Devices. **2018**, 3, 174-182		55
181	Biosensors for Alzheimer's disease biomarker detection: A review. **2018**, 147, 13-24		63
180	An acute functional screen identifies an effective antibody targeting amyloid-β oligomers based on calcium imaging. **2018**, 8, 4634		6
179	Mesoporous Silica and Organosilica Nanoparticles: Physical Chemistry, Biosafety, Delivery Strategies, and Biomedical Applications. **2018**, 7, 1700831		306
178	Amyloid β oligomers (Aβs) in Alzheimer's disease. **2018**, 125, 177-191		72
177	Alzheimer's disease as oligomeropathy. **2018**, 119, 57-70		67
176	Nanotechnology in Personalized Medicine: A Promising Tool for Alzheimer's Disease Treatment. *Current Medicinal Chemistry*, **2018**, 25, 4602-4615	4.3	12
175	Fiber Optic Plasmonic Sandwich Immunosensor: Influence of AuNP Label Size and Concentration. **2018**,		2
174	Triggering microglia through toll-like receptor 2 pathway induced interferon β expression in cell and animal model of Alzheimer's disease. **2018**, 29, 1456-1462		7
173	Stress Biomarkers in Biological Fluids and Their Point-of-Use Detection. **2018**, 3, 2025-2044		89
172	Ultrasensitive detection of T-2 toxin in food based on bio-barcode and rolling circle amplification. **2018**, 1043, 98-106		24
171	Histone-Mimetic Gold Nanoparticles as Versatile Scaffolds for Gene Transfer and Chromatin Analysis. **2018**, 29, 3691-3704		5
170	Efficient biosensing through 1D silver nanostructured devices using plasmonic effect. **2018**, 29, 385501		6
169	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. *Frontiers in Neuroscience*, **2018**, 12, 37	5.1	77
168	Nanomedicine applications in women's health: state of the art. **2018**, 13, 1963-1983		11
167	Targeted Nanoparticle Binding to Hydroxyapatite in a High Serum Environment for Early Detection of Heart Disease. **2018**, 1, 4927-4939		4

166	Application of nanodiagnostics and nanotherapy to CNS diseases. **2018**, 13, 2341-2371		22
165	The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. **2018**, 64, S567-S610		339
164	Nanoparticles With a Specific Size and Surface Charge Promote Disruption of the Secondary Structure and Amyloid-Like Fibrillation of Human Insulin Under Physiological Conditions. **2019**, 7, 480		15
163	Ultrasensitive Detection of Amyloid-β Using Cellular Prion Protein on the Highly Conductive Au Nanoparticles-Poly(3,4-ethylene dioxythiophene)-Poly(thiophene-3-acetic acid) Composite Electrode. **2019**, 91, 11259-11265		23
162	Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. **2019**, 14, 5541-5554		232
161	Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species. *Frontiers in Neuroscience*, **2019**, 13, 659	5.1	122
160	Early mechanisms of amyloid fibril nucleation in model and disease-related proteins. **2019**, 1867, 140264		9
159	Homomeric and Heteromeric Aβ Species Exist in Human Brain and CSF Regardless of Alzheimer's Disease Status and Risk Genotype. **2019**, 12, 176		4
158	Signal Enhancement of Silicon Nanowire Field-Effect Transistor Immunosensors by RNA Aptamer. **2019**, 4, 14765-14771		17
157	Discussion on Advanced Targeted Nanomedical Application Scenarios for Treatment of Some Chronic Diseases. **2019**, 125-143		1
156	Nanotherapeutics Engineered to Cross the Blood-Brain Barrier for Advanced Drug Delivery to the Central Nervous System. **2019**, 73, 8-18		23
155	Functional Titanium Carbide MXenes-Loaded Entropy-Driven RNA Explorer for Long Noncoding RNA PCA3 Imaging in Live Cells. **2019**, 91, 8622-8629		26
154	Bio-barcode detection technology and its research applications: A review. **2019**, 20, 23-32		18
153	Label-Free Optical Detection of Multiple Biomarkers in Sweat, Plasma, Urine, and Saliva. **2019**, 4, 1346-1357		28
152	Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments. **2019**, 14, e0212815		4
151	Properties of Quantum Dots and Their Biological Applications. **2019**, 21-45		
150	Programmable Atom Equivalents: Atomic Crystallization as a Framework for Synthesizing Nanoparticle Superlattices. **2019**, 15, e1805424		19
149	The Pathway to Intelligence: Using Stimuli-Responsive Materials as Building Blocks for Constructing Smart and Functional Systems. **2019**, 31, e1804540		105

148	Nanoparticle formulations in the diagnosis and therapy of Alzheimer's disease. **2019**, 130, 515-526	54
147	Introduction: Alzheimer□ Disease Pathology and Therapeutics. **2019**, 1-6	
146	Metal ion-induced chemiluminescence recovery for highly intensive chemiluminescence bifunctionalized polydopamine nanospheres. **2019**, 7, 14588-14593	5
145	Nanoneuromedicine for management of neurodegenerative disorder. **2019**, 49, 477-490	22
144	Chimeric DNA-Functionalized Titanium Carbide MXenes for Simultaneous Mapping of Dual Cancer Biomarkers in Living Cells. **2019**, 91, 1651-1658	39
143	Kalirin-7 prevents dendritic spine dysgenesis induced by amyloid beta-derived oligomers. **2019**, 49, 1091-1101	8
142	A novel crosslinking protocol stabilizes amyloid □ oligomers capable of inducing Alzheimer's-associated pathologies. **2019**, 148, 822-836	11
141	Prestimulation of Microglia Through TLR4 Pathway Promotes Interferon Beta Expression in a Rat Model of Alzheimer's Disease. **2019**, 67, 495-503	13
140	Advanced Targeted Nanomedicine. **2019**,	2
139	Ultrasensitive detection of staphylococcal enterotoxin B in foodstuff through dual signal amplification by bio-barcode and real-time PCR. **2019**, 283, 338-344	18
138	Neurotheranostics as personalized medicines. **2019**, 148, 252-289	36
137	A sensitive electrochemical strategy via multiple amplification reactions for the detection of E. coli O157: H7. **2020**, 147, 111752	27
136	Recent Advances in Multifunctional Graphitic Nanocapsules for Raman Detection, Imaging, and Therapy. **2020**, 4, 1900440	10
135	Nonstochastic Protein Counting Analysis for Precision Biomarker Detection: Suppressing Poisson Noise at Ultralow Concentration. **2020**, 92, 654-658	5
134	The Effect of Nanoparticles on the Structure and Enzymatic Activity of Human Carbonic Anhydrase I and II. **2020**, 25,	6
133	Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview. **2020**, 20, 100251	37
132	Multifunctional Superparamagnetic Iron Oxide Nanoparticles Conjugated with A□ Oligomer-Specific scFv Antibody and Class A Scavenger Receptor Activator Show Early Diagnostic Potentials for Alzheimer's Disease. **2020**, 15, 4919-4932	15
131	Alkyne-Monofunctionalized Gold Nanoparticles as Massive Molecular Building Blocks. **2020**, 2020, 2325-2334	2

130	Cancer cell-targeted nanoprobe for multilayer imaging of diverse biomarkers and precise photodynamic therapy. **2020**, 56, 15208-15211		1
129	Nanotechnology-based devices in the treatment for Alzheimer disease. **2020**, 241-256		
128	Nanopharmaceuticals: A focus on their clinical translatability. **2020**, 578, 119098		31
127	Different Approaches to Develop Nanosensors for Diagnosis of Diseases. *Advanced Science*, **2020**, 7, 2001476	13.6	14
126	Nanoparticle cellular uptake and intracellular targeting on reactive oxygen species (ROS) in biological activities. **2020**, 373-395		
125	Insulin fibrillation: toward strategies for attenuating the process. **2020**, 56, 11354-11373		19
124	Nanobiotechnology and Its Application in Nanomedicine: An Overview. **2020**, 3-25		1
123	Clinical significance of fluid biomarkers in Alzheimer's Disease. **2020**, 72, 528-542		11
122	Amyloid Metabolism and Amyloid-Targeting Blood-Based Biomarkers of Alzheimer's Disease. **2020**, 75, 685-696		4
121	Advances in amyloid beta oligomer detection applications in Alzheimer's disease. **2020**, 129, 115919		11
120	Application of Nanomaterials in the Diagnosis and Treatment of Genetic Disorders. **2020**, 125-146		7
119	Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of A oligomers?. **2020**, 29, 1748-1759		21
118	Applications of Nanomaterials in Human Health. **2020**,		5
117	Applications of Nanomaterials in Neurological Diseases, Neuronal Differentiation, Neuronal Protection, and Neurotoxicity. **2020**, 83-124		1
116	Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs. *Frontiers in Neuroscience*, **2020**, 14, 494	5.1	61
115	Single-Step, Salt-Aging-Free, and Thiol-Free Freezing Construction of AuNP-Based Bioprobes for Advancing CRISPR-Based Diagnostics. **2020**, 142, 7506-7513		81
114	Glycated albumin precipitation using aptamer conjugated magnetic nanoparticles. **2020**, 10, 10716		4
113	Metallic nanoparticulate delivery systems. **2020**, 279-328		2

112	Nanoengineered biomaterials for neurodegenerative disorders. **2020**, 713-734	1
111	Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers. **2020**, 49, 5446-5472	25
110	Photoelectrochemical Detection of ‖amyloid Peptides by a TiO2 Nanobrush Biosensor. **2020**, 20, 6248-6255	8
109	Neurodegenerative Disease Diagnostics and Therapy of TiO 2 -Based Nanoparticles. **2020**, 217-236	
108	Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's. **2020**, 245, 117394	29
107	Femtomolar sensing of Alzheimer's tau proteins by water oxidation-coupled photoelectrochemical platform. **2020**, 154, 112075	12
106	Oligomerization and Conformational Change Turn Monomeric ‖Amyloid and Tau Proteins Toxic: Their Role in Alzheimer's Pathogenesis. **2020**, 25,	27
105	Recent advances on functional nucleic acid-based biosensors for detection of food contaminants. **2021**, 222, 121565	24
104	Dual-functionalized gold nanoparticles probe based bio-barcode immuno-PCR for the detection of glyphosate. **2021**, 338, 128133	7
103	Dendrimer Architectonics to Treat Cancer and Neurodegenerative Diseases with Implications in Theranostics and Personalized Medicine.. **2021**, 4, 1115-1139	12
102	Nanoconstructs as a versatile tool for detection and diagnosis of Alzheimer biomarkers. **2021**, 32, 142002	6
101	Significance of nanosomes for diagnosis of Alzheimer‖ disease. **2021**, 499-510	
100	Nanomaterials for bioimaging studies. **2021**, 19-34	
99	Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders. **2021**, 291-310	
98	A ‖Amyloid Biosensor Based on Molecularly Imprinted Poly-Pyrrole for Early Diagnosis of Alzheimer's Disease. **2021**, 11, 215-228	1
97	In Vitro Applications of Nanoparticles. *Nanotechnology in the Life Sciences*, **2021**, 41-69	1.1
96	Fluorescence Resonance Energy Transfer (FRET)-Based ThT Free Sensing of Beta-Amyloid Fibrillation by Carbon Dot-Ag Composites. **2021**, 16, 863-872	1
95	Systems and application biopsy. **2021**, 623-712	

94	Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. **2021**, 5, 277-294		10
93	Ultrasensitive monitoring strategy of PCR-like levels for zearalenone contamination based DNA barcode. **2021**, 101, 4490-4497		1
92	Nanomaterial-based Optical and Electrochemical Biosensors for Amyloid beta and Tau: Potential for early diagnosis of Alzheimer's Disease. **2021**, 21, 175-193		4
91	Alzheimer's Disease: Pathogenesis and Therapeutic interventions. **2021**,		3
90	Nanoparticle-based methodologies for targeted drug delivery□n insight. **2021**, 23, 1		5
89	Nanomedicine against Alzheimer's and Parkinson's Disease. *Current Pharmaceutical Design*, **2021**, 27, 1507-1545	3.3	3
88	Plasma amyloid-□ligomerization assay as a pre-screening test for amyloid status. **2021**, 13, 133		6
87	Nanotechnology-Based Strategies for Early Diagnosis of Central Nervous System Disorders. **2021**, 1, 2100008		3
86	Amyloid □ligomer selective antibodies for Alzheimer□ therapeutics and diagnostics.		
85	A Specialized Nutritional Formulation Prevents Hippocampal Glial Activation and Memory Impairment Induced by Amyloid-□Oligomers in Mice. **2021**, 83, 1113-1124		0
84	Nanomedicine: a socio-technical system. **2021**, 173, 121066		1
83	Biosensor fabrication with nanomaterials. **2021**, 31-55		
82	A dopamine metabolite stabilizes neurotoxic amyloid-□ligomers. **2021**, 4, 19		6
81	The Role of Nanomedicine in the Treatment of Neurodegenerative Disorders. **2019**, 49-63		1
80	Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment. **2017**, 57-87		2
79	Molecules that Disrupt Memory Circuits in Alzheimer□ Disease: The Attack on Synapses by A□ Oligomers (ADDLs). **2007**, 155-179		7
78	Why Alzheimer□ is a Disease of Memory: Synaptic Targeting by Pathogenic A□Oligomers (ADDLs). **2008**, 103-132		4
77	Technology for Biotechnology. **2011**, 61-73		1

76	Overview of Fibrillar and Oligomeric Assemblies of Amyloidogenic Proteins. **2012**, 1-36	2
75	The Role of A and Tau Oligomers in the Pathogenesis of Alzheimer Disease. **2012**, 135-188	5
74	Sensitive detection of streptomycin in milk using a hybrid signal enhancement strategy of MOF-based bio-bar code and target recycling. **2020**, 1125, 1-7	15
73	Chapter 2:Chemical and Biological Sensing Using Gold Nanoparticles. **2008**, 29-59	0
72	Inflammation: major denominator of obesity, Type 2 diabetes and Alzheimer's disease-like pathology?. **2020**, 134, 547-570	18
71	Single bead affinity detection (SINBAD) for the analysis of protein-protein interactions. **2008**, 3, e2061	9
70	RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity. **2009**, 4, e7694	43
69	A 0 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. **2010**, 5, e15725	82
68	Expression and localization of mitochondrial ferritin mRNA in Alzheimer's disease cerebral cortex. **2011**, 6, e22325	38
67	Evaluating amyloid- oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. **2013**, 8, e66381	93
66	[New biomarkers and drug targets for diagnosis and therapy of Alzheimer's disease (molecular determinants of zinc-dependent oligomerization of amyloid)]. **2015**, 115, 5-9	4
65	Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. **2008** , 14, 451-64	362
64	Key Peptides and Proteins in Alzheimer's Disease. **2019**, 20, 577-599	14
63	Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective. **2017**, 14, 1164-1181	36
62	Targeting Metal Homeostasis as a Therapeutic Strategy for Alzheimer Disease. 83-98	2
61	A Review on Nanomedicinal and Nanosensing Potential of Nanoparticles. **2014**, 8, 58-84	4
60	Challenges in understanding the structure/activity relationship of A oligomers. **2019**, 6, 1-22	2
59	Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon. **2007**, 9, 32-41	25

58	Revisiting the dilution factor as vital parameter for sensitivity of ELISA assay in CSF and Plasma. **2015**, 22, 37-42	4	
57	Papers of Note. **2005**, 2005, nw6-nw6		
56	Chapter 8 Biosensing with plasmonic nanoparticles. **2006**, 219-270		
55	Nanomedicine: current approach to diagnosis and treatment of diseases and safety issues. **2008**, 5-13	2	
54	Alzheimer's Disease-Related Mechanisms of Neuronal Dysfunction and Degeneration: Studies in Human Cortical Neurons. **2008**, 183-202		
53	Bar Coding Platforms for Nucleic Acid and Protein Detection. **2009**, 315-338		
52	Introducing Nanoneuroscience as a Distinct Discipline. **2009**, 1-34		
51	Biomolecule-Nanoparticle Hybrid Systems. 139		
50	The Nature of Nanotechnology. 3	0	
49	Nanomedicine and Neurodegenerative Disorders. **2011**,		
48	Biological Targeting and Activity of Pre-fibrillar Aβ Assemblies. **2012**, 103-133		
47	Nanoparticle-Based Immunoassays and their Applications in Nervous System Biomarker Detection. **2012**, 17-37		
46	Emerging Principles and Biomarkers in In Vitro Diagnostics for Alzheimer's Disease. **2012**, 87-102		
45	Peptidome analysis: tools and technologies. **2013**, 172-202		
44	Insulin Receptor and the Pathophysiology of Alzheimer Disease. 31-50		
43	Nanomedicines for Nervous System Diseases. **2014**, 2125-2156		
42	Alzheimer's Disease and Other Neurodegenerative Disorders. **2015**, 329-351		
41	Enhanced neuronal degradation of amyloid-β oligomers allows synapse regeneration. *Neural Regeneration Research*, **2015**, 10, 700-1	4.5	1

40	Immunotherapy and Vaccines. **2016**, 441-464		
39	Memeli Tmi ve Normal Hre Hatlarda Nanopartik Uygulamalar. *Arsiv Kaynak Tarama Dergisi*, **2018**, 27, 136-174	0.1	0
38	Diyet Yla Alzheimer Hastal Patolojisi erine Potansiyel Koruyucu Etkileri. *Sa Salk Bilimleri Dergisi*,	0	
37	Nanotechnology in Early Detection and Treatment of Amyloidosis. *Nanotechnology in the Life Sciences*, **2020**, 185-207	1.1	
36	Recent Advances in Nanotherapeutic Interventions for the Treatment of Alzheimer's Disease. *Current Pharmaceutical Design*, **2020**, 26, 2257-2279	3.3	0
35	Nanotechnology: Application in Biology and Medicine. **2020**, 1-18		
34	Drug delivery nanosystems for neural regenerative medicine. **2020**, 89-122		
33	Ultrasensitive measurement of protein and nucleic Acid biomarkers for earlier disease detection and more effective therapies. *Biotechnology Healthcare*, **2006**, 3, 35-40		7
32	Alzheimer's Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station. *Yale Journal of Biology and Medicine*, **2017**, 90, 45-61	2.4	17
31	Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics. **2019**, 7, 547-558		
30	Bio-nano Interface and Its Potential Application in Alzheimer Disease. **2022**, 209-224		0
29	The Therapeutic and Diagnostic Potential of Amyloid Oligomers Selective Antibodies to Treat Alzheimer's Disease.. *Frontiers in Neuroscience*, **2021**, 15, 768646	5.1	0
28	Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention.. *Ageing Research Reviews*, **2021**, 74, 101544	12	3
27	Nano-Biosensors from Agriculture to Nextgen Diagnostic Tools. *Current Nanomaterials*, **2022**, 07,	1.3	
26	Size and macromolecule stabilizer-dependent performance of gold colloids in immuno-PCR.. *Analytical and Bioanalytical Chemistry*, **2022**, 414, 2205	4.4	0
25	Progress of Nanotechnology-Based Detection and Treatment of Alzheimer Disease Biomarkers. **2022**, 47-88		
24	Metal nanoparticles for neurodegenerative diseases. **2022**, 183-206		0
23	An Essential Role for Alzheimer's-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	1

22	Multifunctional Gold Nanoparticles for Improved Diagnostic and Therapeutic Applications: A Review. *Nanoscale Research Letters*, **2021**, 16, 174	5	9
21	Nanodelivery of nucleic acids.. *Nature Reviews Methods Primers*, **2022**, 2,		11
20	Ultrasensitive immuno-PCR for detecting aflatoxin B1 based on magnetic separation and barcode DNA. *Food Control*, **2022**, 109028	6.2	1
19	Data_Sheet_1.pdf. **2019**,		
18	Applications of Gold Nanoparticles in Brain Diseases across the Blood-Brain Barrier.. *Current Medicinal Chemistry*, **2022**, 29,	4.3	
17	AAV-mediated neuronal expression of a scFv antibody selective for Aβ oligomers protects synapses and rescues memory in Alzheimer models.		
16	Diagnostic and Therapeutic Systems Using Nanomaterials. **2022**, 1-56		
15	Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases. *Advanced Science*, 2201740	13.6	2
14	Functional Principal of Nanotechnology in Clinical Research. **2022**, 33-73		
13	Nanotechnology for the diagnosis and treatment of Alzheimer's disease: A bibliometric analysis. **2022**, 47, 101654		0
12	AAV-mediated neuronal expression of a scFv antibody selective for Aβ oligomers protects synapses and rescues memory in Alzheimer models. **2022**,		0
11	Non-viral nucleic acid delivery approach: A boon for state-of-the-art gene delivery. **2023**, 80, 104152		0
10	TRPV4 mRNA is elevated in the caudate nucleus with NPH but not in Alzheimer's disease. 13,		0
9	Nanomaterial-based Clinical Testing and Diagnostic Technologies. 40, 132-141		0
8	Recent advances in plasmon-enhanced luminescence for biosensing and bioimaging. **2023**, 1254, 341086		0
7	DNAzyme-driven tripedal DNA walker triggered hybridization chain reaction for label-free electrochemical detection of Alzheimer's tau protein. **2023**, 384, 133656		0
6	Plantainoside B in <i>Bacopa monniera</i> Binds to Aβ Aggregates Attenuating Neuronal Damage and Memory Deficits Induced by Aβ **2023**, 46, 320-333		0
5	Nanotechnology to the Rescue: Therapeutic Strategies Based on Brown Algae for Neurodegenerative Diseases. **2023**, 13, 1883		1

4	Brain region-specific myelinogenesis is not directly linked to amyloid-β in APP/PS1 transgenic mice. **2023**, 362, 114344	0
3	Glucometer-based biosensor for the determination of ractopamine in animal-derived foods using rolling circle amplification. **2023**, 190,	0
2	A new class of monoclonal Aβ antibodies selectively targets and triggers deposition of Aβ protofibrils.	0
1	Antibodies Raised Against an Aβ Oligomer Mimic Recognize Pathological Features in Alzheimer's Disease and Associated Amyloid-Disease Brain Tissue.	0